Core Scientific (CORZW) EBIAT (2020 - 2026)

Core Scientific has disclosed EBIAT across 7 years of filings, most recently posting -$347.2 million for Q1 2026.

• EBIAT for Q1 2026 came in at -$347.2 million, down 160.25% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.2 billion (down 13.03% YoY), and the FY2025 annual result was -$288.6 million, up 79.93% from the prior year.
• EBIAT came in at -$347.2 million for Q1 2026 at Core Scientific, down from $216.0 million in the prior quarter.
• In the past five years, EBIAT ranged from a high of $576.3 million in Q1 2025 to a low of -$936.8 million in Q2 2025.
• The 5-year median for EBIAT is -$291.1 million (2024), against an average of -$262.7 million.
• Across the five-year window, EBIAT slumped 23639.75% in 2022 and surged 54401.8% in 2024, its largest moves.
• Core Scientific's EBIAT stood at -$434.8 million in 2022, then surged by 55.0% to -$195.7 million in 2023, then slumped by 48.78% to -$291.1 million in 2024, then surged by 174.17% to $216.0 million in 2025, then plunged by 260.77% to -$347.2 million in 2026.
• The last three EBIAT figures came in at -$347.2 million (Q1 2026), $216.0 million (Q4 2025), and -$144.0 million (Q3 2025), per Business Quant data.